Abstract 2731
Background
Cardiovascular disease (CVD) is the leading cause of death worldwide. With improved cancer treatment and survivorship, CVD and other non-cancer events compete with cancer as the underlying cause of death. However, their mortality risk in competing risk settings is not well characterised.
Methods
We identified 21,637 individuals with a first cancer registered between January 2006 and December 2013 in the population-based Tasmanian Cancer Registry, Australia. Cumulative incidence functions were applied to assess the cumulative incidence of deaths due to specific competing events with follow-up to December 2015. Standardised mortality ratios (SMRs) and absolute excess risks (AERs) for non-cancer deaths were calculated to allow comparison with the general population.
Results
Overall, 8,844 deaths were observed with 1,946 (22.0%) from competing events (332 from subsequent cancer, 741 from CVD and 873 from other non-cancer events). The cumulative incidence of deaths due to CVD increased significantly with age at first cancer diagnosis (5-year cumulative mortality by age group: 15-64y – 0.7%; 65-74y – 2.1%; 75-84y – 6.0%; 85+y – 13.1%) and exceeded other competing events for those with a first cancer diagnosis at age 65 years or older. For the whole follow-up period, CVD deaths were as expected for the general population (SMR, 0.97; 95%CI 0.90-1.04), however within the first follow-up year, CVD deaths were more common than expected (SMR, 1.44; 95%CI 1.26-1.64; AER, 36.8/10,000 person-years). The SMR and AER for CVD deaths varied by first cancer sites showing an increased risk after a first diagnosis of lung cancer, haematological malignancies and urinary tract cancers. For other non-cancer events, the SMRs significantly increased for infectious disease and respiratory disease for the whole follow-up and within the first year of diagnosis.
Conclusions
CVD was the leading cause of competing mortality among Tasmanian cancer patients diagnosed from 2006-2013. The higher than expected risk of death due to CVD and other non-cancer events was greatest during the first year after cancer diagnosis highlighting the importance of early preventive interventions.
Clinical trial identification
Legal entity responsible for the study
Menzies Institute for Medical Research, University of Tasmania.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract